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ABSTRACT
Background: Lung clearance index (LCI) derived from
sulfur hexafluoride (SF6) multiple breath washout (MBW)
is a sensitive measure of lung disease in people with
cystic fibrosis (CF). However, it can be time-consuming,
limiting its use clinically.
Aim: To compare the repeatability, sensitivity and test
duration of LCI derived from washout to 1/30th (LCI1/30),
1/20th (LCI1/20) and 1/10th (LCI1/10) to ‘standard’ LCI
derived from washout to 1/40th initial concentration
(LCI1/40).
Methods: Triplicate MBW test results from 30 clinically
stable people with CF and 30 healthy controls were
analysed retrospectively. MBW tests were performed
using 0.2% SF6 and a modified Innocor device. All LCI
end points were calculated using SimpleWashout
software. Repeatability was assessed using coefficient of
variation (CV%). The proportion of people with CF with
and without abnormal LCI and forced expiratory volume
in 1 s (FEV1) % predicted was compared. Receiver
operating characteristic (ROC) curve statistics were
calculated. Test duration of all LCI end points was
compared using paired t tests.
Results: In people with CF, LCI1/40 CV% (p=0.16), LCI1/
30 CV%, (p=0.53), LCI1/20 CV% (p=0.14) and LCI1/10 CV
% (p=0.25) was not significantly different to controls.
The sensitivity of LCI1/40, LCI1/30 and LCI1/20 to the
presence of CF was equal (67%). The sensitivity of LCI1/
10 and FEV1% predicted was lower (53% and 47%
respectively). Area under the ROC curve (95% CI) for
LCI1/40, LCI1/30, LCI1/20, LCI1/10 and FEV1% predicted was
0.89 (0.80 to 0.97), 0.87 (0.77 to 0.96), 0.87 (0.78 to
0.96), 0.83 (0.72 to 0.94) and 0.73 (0.60 to 0.86),
respectively. Test duration of LCI1/30, LCI1/20 and LCI1/10
was significantly shorter compared with the test duration
of LCI1/40 in people with CF (p<0.0001) equating to a
5%, 9% and 15% time saving, respectively.
Conclusions: In this study, LCI1/20 was a repeatable and
sensitive measure with equal diagnostic performance to
LCI1/40. LCI1/20 was shorter, potentially offering a more
feasible research and clinical measure.
INTRODUCTION
Lung Clearance Index (LCI) derived from
multiple breath washout (MBW) is a sensitive
measure of ventilation inhomogeneity1 2 and
a robust surrogate outcome measure of the
severity of lung disease in cystic ﬁbrosis (CF)3
which has begun to be incorporated into
clinical trials.4 5 It also shows promise as a
sensitive outcome measure in idiopathic
bronchiectasis6 and asthma.7 A drawback of
the test is that it can be time-consuming,
especially in patients with advanced disease,
limiting its feasibility within the clinical envir-
onment. By convention a MBW test involves
performing a minimum of three inert tracer
gas washout runs, ending the washout when
end-tidal tracer gas concentration falls below
1/40th of the initial concentration.8 The end
point of 1/40th is based on historic studies
and has not been systematically validated.8 9
The European Respiratory Society/American
Thoracic Society (ERS/ATS) consensus state-
ment highlights investigation of the ﬂexibility
of current MBW test end points as an
important area for future research, which
could potentially improve the utility of this
test.8 Assessment of the clinimetric proper-
ties of shortened LCI in CF using nitrogen
(N2) MBW testing (100% as the inert gas),
have reported good diagnostic performance
in children with mild disease, offering a
measure of ventilation inhomogeneity which
may be more practical in the clinical
setting.10 However, there are no studies to
assess the performance of shortened LCI
using sulfur hexaﬂuoride (SF6) MBW
KEY MESSAGES
▸ Lung Clearance Index (LCI) can be time-
consuming, limiting its use clinically.
▸ Investigation of the flexibility of current multiple
breath washout test end points is an important
area for future research.
▸ LCI1/20 is a repeatable and sensitive test that is
shorter than LCI1/40, potentially offering a more
feasible research and clinical measure.
Hannon D, Bradley JM, Bradbury I, et al. BMJ Open Resp Res 2014;1:e000031. doi:10.1136/bmjresp-2014-000031 1
Cystic fibrosis
 group.bmj.com on July 30, 2014 - Published by bmjopenrespres.bmj.comDownloaded from 
(another common MBW method), or studies of shor-
tened LCI in adult patients with more moderate to
advanced disease. Differences in gas diffusion and
molecular mass of the inert gases used mean that results
of the two types of test are not comparable.11 Study of
the sensitivity of shortened MBW tests using SF6 could
be useful in improving the clinical utility of these tests.
In this study we aimed to assess and compare the
repeatability, sensitivity, speciﬁcity and test duration of
LCI derived from washout to 1/30th (LCI1/30), 1/20th
(LCI1/20) and 1/10th of the initial concentration
(LCI1/10) to ‘standard’ LCI derived from washout to
1/40th initial concentration (LCI1/40), using 0.2% SF6
as the tracer gas, in school age—adolescent children
and adults with CF and healthy controls.
METHODS
Subject recruitment
Cross-sectional data from 30 people with CF (n=15 aged
6–17 years old; n=15 aged ≥18 years old) and 30 healthy
control participants (n=15 aged 6–17 years old; n=15
aged ≥18 years old) with three valid and repeatable
MBW tests were analysed. Thirty anonymised CF and 30
healthy control data sets, as consecutively listed in a
database of results collected in a large prospective
project investigating the clinimetric and clinical rele-
vance of LCI in CF were used. People with CF were
recruited at a routine outpatient visit to the Northern
Ireland paediatric and adult CF centres at Belfast Health
and Social Care Trust (BHSCT), when clinically stable
(no pulmonary exacerbation requiring intravenous anti-
biotics in the previous 4 weeks), between October 2010
and June 2013. Control participants were recruited by
means of email circulation among people employed in
Queen’s University Belfast (QUB) and BHSCT between
September 2011 and August 2012. All adult participants
provided written informed consent. All child partici-
pants provided child or young person assent and paren-
tal consent.
MBW testing
The MBW test to measure LCI was carried out using a
modiﬁed Innocor device and 0.2% SF6 using the open-
circuit technique in accordance with the standard oper-
ating procedure developed by the UK CF Gene Therapy
Consortium (UKCFGTC; see online supplementary ﬁle
1) as described and validated by Horsley et al2 and used
in a recent CF clinical trial and observational study.4 12
Participants breathed through a mouthpiece at tidal
volumes, while in a seated position and wearing a nose
clip. Participants breathed 0.2% SF6 in air via a ﬂowpast
circuit until washin was complete, at which point the
ﬂowpast was disconnected and the participant breathed
room air until the end tidal expired SF6 concentration
fell below 1/40th of the initial concentration before dis-
connection. Three washouts were performed for each
participant. Analysis of MBW data was performed using
the SimpleWashout programme developed by Dr
Nicholas Bell (UKCFGTC) and used with his permission
(see online supplementary ﬁle 1). For each washout,
four values for functional residual capacity (FRC) and
LCI were calculated:
▸ FRC1/40 and LCI1/40 were derived from washout data
from ﬂowpast disconnection until the ﬁrst breath
with end tidal SF6 concentration below 1/40th
(≤0.005%) of the starting SF6 concentration (0.2%).
▸ FRC1/30 and LCI1/30 were derived from washout data
from ﬂowpast disconnection until the ﬁrst breath
with end tidal SF6 concentration below 1/30th
(≤0.007%) of the starting SF6 concentration (0.2%).
▸ FRC1/20 and LCI1/20 were derived from washout data
from ﬂowpast disconnection until the ﬁrst breath
with end tidal SF6 concentration below 1/20th
(≤0.01%) of the starting SF6 concentration (0.2%).
▸ FRC1/10 and LCI1/10 were derived from washout data
from ﬂowpast disconnection until the ﬁrst breath
with end tidal SF6 concentration below 1/10th
(≤0.02%) of the starting SF6 concentration (0.2%).
Mean LCI and FRC values and test duration (minutes)
for each end point were calculated from each of the
three washouts in each testing session.
Spirometry
Spirometry was measured according to American
Thoracic Society/European Respiratory Society ATS/
ERS guidelines13 using a Microlab (ML3500 MK8) spir-
ometer (CareFusion, Kent, UK). Predicted values were
calculated from reference ranges for all ages.14
Statistical analysis
Data were analysed using PASW Statistics (V.18, IBM soft-
ware, USA) and Prism (V.5.01 GraphPad Software Inc.)
packages. CF and control participant characteristics were
summarised using descriptive statistics.
Intravisit repeatability of LCI1/40, LCI1/30 LCI1/20 and
LCI1/10 was assessed using the coefﬁcient of variation
(CV%) of all three tests and Bland-Altman plots15 com-
paring tests one and three, for people with CF and
healthy controls. Results between people with CF and
healthy controls were compared using an independent
samples t test. Mean LCI and FRC values for each end
point from people with CF or healthy controls were com-
pared using paired samples t tests. The relationship
between mean LCI1/40 and mean LCI1/30, LCI1/20 and
LCI1/10 was assessed using scatter plots and the
Spearman’s rank correlation coefﬁcient. This analysis
was also used to assess the relationship between FEV1%
predicted and all LCI end points. Sensitivity of all LCI
end points compared with FEV1% predicted was
assessed using scatter plots and limits of normal of
respective tests calculated from healthy controls (mean
+1.96 SD). Sensitivity and speciﬁcity were further ana-
lysed using receiver operating characteristic (ROC)
curves, and by comparing area under the ROC curve
(AUCROC) and 95% CI for LCI1/40, LCI1/30, LCI1/20,
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LCI1/10 and FEV1% predicted. Mean test duration
(minutes) of LCI1/40, LCI1/30, LCI1/20 and LCI1/10 was
compared using a paired samples t test. As multiple
comparisons were being made, a Bonferroni adjustment
was incorporated. A p value of <0.01 was considered stat-
istically signiﬁcant.
RESULTS
LCI1/40, LCI1/30, LCI1/20, LCI1/10 and FEV1% predicted
were signiﬁcantly different between the CF and control
group. However, there was no difference between the CF
and control group in age, sex, LCI1/40 CV%, LCI1/30 CV
%, LCI1/20 CV%, LCI1/10 CV% or test duration of any
LCI end point (table 1).
There was no difference between the CF and control
group in any of the FRC values (FRC1/40, FRC1/30,
FRC1/20 or FRC1/10). Within the CF group, as expected,
FRC was incrementally lower with each earlier end
point. Although FRC1/40, and FRC1/30 were not signiﬁ-
cantly different (1.95 vs 1.93, p=0.07) FRC1/40 and
FRC1/20 (1.95 vs 1.90, p=0.002) and FRC1/40 and
FRC1/10 (1.95 vs 1.84) were signiﬁcantly different.
Intravisit repeatability
LCI1/40 CV%, LCI1/30 CV%, LCI1/20 CV% and LCI1/10
CV% in people with CF were not signiﬁcantly different
to values in healthy controls (table 1). There was also no
signiﬁcant difference between LCI1/40 CV% and the CV
% of any other LCI end point in people with CF. A
Bland-Altman plot15 of the mean versus the difference
between tests one and three of LCI1/40, LCI1/30, LCI1/20
and LCI1/10 for people with CF showed no evidence of
greater variability in participants with more advanced
disease (ie, a higher LCI reading; ﬁgure 1A–D).
For LCI1/40, the 95% limits of agreement between the
two measurements were −1.70 to 1.33 lung turnovers,
compared with −1.33 to 1.07 (LCI1/30), −1.43 to 0.96
(LCI1/20) and −0.83 to 0.66 (LCI1/10) lung turnovers.
Therefore the intravisit repeatability of the LCI1/40,
LCI1/30, LCI1/20 and LCI1/10 measurements was 1.5, 1.2,
1.2 and 0.7 lung turnovers respectively.
Relationship between shortened LCI and ‘standard’ LCI1/40
In people with CF, LCI1/30 (r=0.98, p<0.0001), LCI1/20
(r=0.95, p<0.0001) and LCI1/10 (r=0.88, p<0.0001) corre-
lated signiﬁcantly with LCI1/40 (ﬁgure 2).
Sensitivity and specificity
The upper limit of normal for LCI1/40, LCI1/30, LCI1/20
and LCI1/10 was 7.3, 6.7, 5.9 and 4.6 lung turnovers,
respectively, (control mean +1.96 SD). The lower limit of
normal of 80% for FEV1% predicted was used, as this is
the level that is historically used in clinical practice.
The sensitivity of LCI1/40, LCI1/30, LCI1/20 to differenti-
ate between people with CF and healthy controls was iden-
tical (67%). The sensitivity of LCI1/10 and FEV1%
predicted was lower (53% and 47%, respectively). In
people with CF, LCI1/40 (r=−0.73, p<0.0001), LCI1/30
(r=−0.70, p<0.0001), LCI1/20 (r=−0.69, p<0.0001) and
LCI1/10 (r=−0.62, p=0.0003) correlated signiﬁcantly with
FEV1% predicted (ﬁgures 3A–D). Using LCI1/40, 6/30
(20%) people with CF had an abnormal LCI in the
Table 1 CF and healthy control participant characteristics
People with CF Healthy controls p Value (CF vs controls)
N 30 30 –
M/F 14/16 16/14 0.61
Age (years) 20.7 (11.1) (6–51) 20.8 (10.7) (7–44) 0.93
FEV1 (% predicted) 79.3 (17.9) (46.0–116.0) 92.9 (11.3) (68.0–116.0) 0.009
FRC1/40 (L) 1.95 (0.76) 2.23 (1.0) 0.22
LCI1/40 (number of turnovers) 9.0 (2.4) 6.4 (0.5) <0.0001
LCI1/40 CV% 5.2 (2.8) 4.3 (2.0) 0.16
LCI1/40 triplicate test duration (min) 21.8 (9.7) (8.0–57.1) 19.4 (6.5) (10.1–31.1) 0.26
FRC1/30 (L) 1.93 (0.76) 2.24 (1.02) 0.18
LCI1/30 (number of turnovers) 7.7 (1.6) 5.9 (0.4) <0.0001
LCI1/30 CV% 4.6 (3.2) 4.1 (2.8) 0.53
LCI1/30 triplicate test duration (min) 20.9 (9.1) (7.3–53.2) 18.9 (6.2) (9.9–29.9) 0.34
FRC1/20 (L) 1.90 (0.75) 2.24 (1.0) 0.15
LCI1/20 (number of turnovers) 6.6 (1.2) 5.2 (0.4) <0.0001
LCI1/20 CV% 5.7 (3.4) 4.6 (2.3) 0.14
LCI1/20 triplicate test duration (min) 20.0 (8.9) (6.7–51.7) 18.3 5.9 (9.6–28.3) 0.38
FRC1/10 (L) 1.84 (0.73) 2.22 (1.00) 0.09
LCI1/10 (number of turnovers) 4.7 (0.6) 4.0 (0.3) <0.0001
LCI1/10 CV% 5.4 (3.8) 4.3 (2.8) 0.25
LCI1/10 triplicate test duration (min) 18.6 (8.1) (5.7–46.9) 17.1 (5.5) (8.8–26.6) 0.41
All values summarised as mean (SD)±(range).
CF, cystic fibrosis; CV, coefficient of variation, F, female; FEV1, forced expiratory volume in 1 s; FRC, functional residual capacity; LCI, Lung
Clearance Index; M, male.
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presence of a normal FEV1% predicted (ﬁgure 3A).
Similarly, using LCI1/30 or LCI1/20, 7/30 (23%) people
with CF had an abnormal LCI in the presence of a normal
FEV1% predicted (ﬁgure 3B–C). LCI1/10 was less sensitive,
detecting 5/30 (17%) with an abnormal LCI in the pres-
ence of a normal FEV1% predicted (ﬁgure 3D).
ROC curve analysis (ﬁgure 4) showed that while all
LCI values and FEV1% predicted had statistically signiﬁ-
cant levels of sensitivity and speciﬁcity in determining
people with CF vs control participants, LCI1/40, LCI1/30
and LCI1/20 had comparable and higher sensitivity and
speciﬁcity compared with LCI1/10 and FEV1% predicted
(table 2).
Test duration
Test duration of LCI1/30, LCI1/20 and LCI1/10 was signiﬁ-
cantly shorter compared with washout duration of LCI1/
40 in people with CF (p<0.0001) and in healthy controls
(p<0.0001; table 1). In people with CF, the mean (95%
CI) time saving per triplicate MBW test was 1 (0.8 to
1.3) minutes or 5% with LCI1/30, 1.9 (1.4 to 2.3)
minutes or 9% with LCI1/30 and 3.3 (2.6 to 4.2) minutes
or 15% with LCI1/10.
DISCUSSION
This study is the ﬁrst to show that SF6 MBW tests can be
reliably shortened. Results show that in children and
adults with CF, LCI shortened to 1/30th or 1/20th
(LCI1/30 or LCI1/20) of the initial concentration have
comparable intravisit repeatability and sensitivity to
‘standard’ LCI at 1/40th of the starting concentration
(LCI1/40) providing additional information to FEV1%
predicted and offering a time saving. Although repeat-
able, LCI shortened to 1/10th of the starting concentra-
tion (LCI1/10) was less sensitive to lung disease,
compared with the other LCI end points. It was,
however, still more sensitive than FEV1% predicted.
Figure 1 (A) Lung Clearance Index (LCI)1/40; (B) LCI1/30; (C) LCI1/20; (D) LCI1/10 first and third test in people with cystic
fibrosis (dotted horizontal lines represent the bias and 95% limits of agreement).
Figure 2 Shortened Lung Clearance Index (LCI) versus
standard LCI1/40 in people with cystic fibrosis.
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The ‘standard’ end point of 1/40th is based on his-
toric studies using nitrogen washout (2.5%) and has not
been systematically validated for MBW tests using SF6.
8 9
This study aimed to assess the performance of earlier
arbitrary end points compared with the ‘standard’ end
point in the SF6 washout, in an attempt to improve the
clinical utility of the MBW test by reducing test duration.
Like LCI1/40, LCI1/30 and LCI1/20 target the ﬂatter tail
of the washout curve, making it unsurprising that similar
information can be obtained (see online supplementary
ﬁle 2). In contrast, when using LCI1/10, the end point
occurs before the washout curve ﬂattens. This supports
the theory that most information is contained in the tail
of the washout curve.16 Therefore a cut-off before this
point may provide less information about lung disease
severity, as highlighted by the lower sensitivity of LCI1/10
in this study. Yammine et al
10 assessed the repeatability
and sensitivity of shortened N2 MBW to measure LCI, at
a number of earlier end points including 1/20th of the
starting concentration and as early as 1/5th of the
Figure 3 Forced expiratory volume in 1 s (FEV1)% predicted versus (A) LCI1/40; (B) LCI1/30; (C) LCI1/20 (D) LCI1/10
(dotted horizontal lines represent the limits of normal for FEV1% predicted (80% predicted) and LCI (LCI1/40:7.3; LCI1/30:6.7;
LCI1/20:5.9; LCI1/10:4.6)).
Figure 4 Receiver operating
characteristic ROC curve of Lung
Clearance Index (LCI)1/40, LCI1/
30, LCI1/20, LCI1/10 and inverse
forced expiratory volume in 1 s %
predicted: sensitivity and
specificity to the presence of
cystic fibrosis CF.
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starting concentration, in 68 children with CF (n=44
with mild disease). In agreement with results from our
study, they reported good performance of shortened
LCI at 1/20th of the starting concentration compared
with ‘standard’ LCI. Furthermore, as with the results
from our study, Yammine et al10 found that while the
earlier LCI end points had good intravisit repeatability,
they were less sensitive and speciﬁc to the presence of
CF. The authors concluded that shortened N2 MBW to
1/20th of the starting concentration could offer a more
feasible measure for use in clinical practice. In this study
we extended these observations to investigate and
conﬁrm the utility of shortened ventilation indices in
older patients with more advanced disease.
Theoretically, in cases of severe ﬂow asynchrony between
the best and the least ventilated lung units, the end-tidal
concentrations in subsequent breathing cycles can
enhance the contribution of the least ventilated units
toward the end of the washout where LCI is measured.16
This may lead to increased variation in results taken at
an earlier end point, such as 1/20th of the starting con-
centration. In contrast, LCI from an earlier end point
may be more precise, as an end point where the
washout curve slope is greater may avoid random
breath-by-breath variability that could be observed at a
later end point. In this study, LCI1/30 and LCI1/20 had
marginally better sensitivity to the presence of CF (23%
vs 20%), compared with LCI1/40, even though there was
no signiﬁcant difference in variability (LCI CV%)
between ‘standard’ LCI (LCI1/40) and LCI at an earlier
end point (LCI1/30, LCI1/20, LCI1/10). LCI1/30 and
LCI1/20 also had good diagnostic performance and
superior sensitivity compared with FEV1% predicted.
Importantly, these ﬁndings indicate that no further add-
itional information was obtained using LCI1/40 com-
pared with the shortened versions, LCI1/30 and LCI1/20.
Test duration for LCI1/30, LCI1/20 and LCI1/10 was sig-
niﬁcantly shorter than LCI1/40 in people with CF, with
an average 5%, 9% and 15% time saving, respectively. As
LCI1/20 offers a greater time saving than LCI1/30, while
maintaining reliability and sensitivity, it provides the
most attractive measure and may enhance the feasibility
of MBW in the research and clinical setting. The propor-
tion of time saved in this study is smaller than that
reported in the study by Yammine et al10 as MBW tests
using an exogenous gas such as SF6 require a washin
and a washout phase. However, as these results are from
a retrospective analysis, the time saving measurement
does not take into account the total time saving per
testing session. Finishing a test earlier would allow for
the second and third test of the triplicate to start sooner,
resulting in a larger time saving. Although the washin
time is unchanged, any shortening of LCI test duration
could be especially useful in younger children where
long assessment periods are not feasible, and in patients
with advanced disease, where the washin and/or
washout periods can be prolonged. The use of MBW
equipment using SF6 has been successfully used in multi-
centre studies and remains popular as it has advantages
in terms of tracer gas estimation (measured directly
rather than by subtraction as with N2 MBW) avoiding
the potential confounding effects of 100% O2 on breath-
ing pattern. This study is the ﬁrst to show that MBW
using SF6 can be reliably shortened.
Considering potential limitations of shortened MBW
tests, one study highlights that advanced analysis of
washout curves to determine the relative contribution of
convective and acinar airways to ventilation heterogen-
eity (phase III analysis) usually requires six lung-volume
turnovers.17 However, recent work suggests that the same
information may be obtainable in three lung-volume
turnovers18 in which case use of LCI1/20 would still
enable full phase III analysis. Regardless, phase III
indices may have limited utility in CF, as demonstrated
by Horsley et al.19
The retrospective nature of this study is a limitation.
However, the study did endeavour to avoid selection bias
by use of anonymsied patient data sets as consecutively
listed in a database and represents the ﬁrst exploratory
study to report on the clinimetric properties of an
earlier end point in SF6 MBW. More data from across
the disease severity range in CF are required to deﬁne
normal ranges of shortened LCI.
CONCLUSIONS
LCI1/20 is a repeatable and sensitive test with equal diag-
nostic performance to LCI1/40 that is shorter, potentially
offering a more feasible research and clinical measure.
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Table 2 AUCROC and 95% CI for LCI1/40, LCI1/30, LCI1/20
LCI1/10 and inverse FEV1% predicted (1.0 indicating best
performance, 0.5 indicating poor performance)
AUCROC 95% CI p Value
LCI1/40 0.89 0.80 to 0.97 <0.0001
LCI1/30 0.87 0.77 to 0.96 <0.0001
LCI1/20 0.87 0.78 to 0.96 <0.0001
LCI1/10 0.83 0.72 to 0.94 <0.0001
FEV1% predicted
(inverse)
0.73 0.60 to 0.86 0.002
AUC, area under the curve; FEV1, forced expiratory volume in 1 s;
LCI, Lung Clearance Index, ROC, receiver operating characteristic
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